Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab subcutaneous phase 2/3 study in adults with systemic sclerosis-associated interstitial lung disease
MOH_2023-08-14_012877Phase 3Not yet recruiting
- Sponsor
- GSK
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD) and systemic sclerosis (SSc) comparing Belimumab plus usual care with Placebo plus usual care (2 arms). Primary endpoint: Reduction in lung volume decline versus placebo. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
belimumab
03
Conditions
pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD)systemic sclerosis (SSc)
Beyond the preview
Go deeper on MOH_2023-08-14_012877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-08-14_012877.